Aktieägarna i Diagonal Bio AB, org.nr 559248-8984, kallas härmed till extra bolagsstämma fredagen den 17 januari 2025 kl. 13.00 på Medicon Village, i huvudbyggnaden The Spark, Scheeletorget 1, Lund.
Read moreBoard of Directors of Diagonal Bio AB (”Diagonal Bio” or the ”Company”) has today resolved on a directed issue of units consisting of shares and consideration free warrants of series TO 2, of initially approximately SEK 1.7 million (the “Directed Issue”), and on a rights issue of units consisting of shares and consideration free warrants of series TO 2, of initially approximately SEK 6.0 million, with preferential rights for the Company’s existing shareholders (the “Rights Issue”, and together with the Directed Issue the “Transaction”). The Transaction is subject to approval by the extraordinary general meeting to be held on 17 January 2025 (the “EGM”). The purpose of the Transaction is to provide funds to focus on validation of LAMPlify®’s commercial interest. The Directed Issue is directed to the Company marketing partner Daniel Redén, through Redén Trotting AB, and the strategic investor Svea Bank AB. The Rights Issue is covered by subscription undertakings from the Board members, the CEO, and other shareholders, of in total approximately SEK 0.4 million, corresponding to approximately 6 percent of the Rights Issue. In addition, Diagonal Bio has received underwriting commitments from the Company’s CEO Karin Wehlin, the Board members and a numbThe er of external investors of a total of SEK approximately 3 million, corresponding to approximately 50 percent of the Rights Issue, which means that the Rights Issue in total is covered by subscription and underwriting commitments of 56 percent. The Board members and CEO Karin Wehlin have entered into customary lock-up agreements corresponding to 100 percent of their respective shareholdings until 31 July 2025. Notice to the EGM will be published through a separate press release. In connection with the Transaction, Diagonal Bio has engaged Navia Corporate Finance AB as the financial advisor. Due to the Transaction, the Company has decided to postpone the release of the Company’s year-end report to 28 March 2025.
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces that Daniel Redén, a renowned horse trainer at StallZet, has entered into a partnership with Diagonal Bio and will act as a marketing partner for the Company to enhance the commercialisation plans for the Company’s platform, LAMPlify®️. StallZet, one of Sweden’s leading trotting facilities with over 190 horses, is collaborating with Diagonal Bio in the ongoing pilot test of LAMPlify®️. As a marketing partner to Diagonal Bio, Daniel Redén will play a key role in showcasing the benefits of LAMPlify® and promoting the product. His extensive experience and wide-ranging network within the trotting and equestrian industries, both nationally and internationally, make him a valuable addition to Diagonal Bio’s commercialisation plans.
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces that one of Sweden’s most accomplished horse race trainers, Madeleine Smith, has initiated a six-month pilot test of LAMPlify®. The pilot test will focus on enhancing equine health and performance through early detection of potential respiratory viruses in horses. The test will be conducted via Madeleine Smith’s horse race training operation M. Smith Galopp.
Read moreDiagonal Bio today announces that the Nomination Committee has been appointed in preparation for the Annual General Meeting (AGM) on May 20, 2025.
Read more
